Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma

Molecular Cancer Therapeutics

Volumn 6, Issue 1, 2007, Pages 138-146

  Huynh, Hung ^a   Soo, Khee Chee ^b   Chow, Pierce K H ^b   Tran, Evelyn ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARRY 142886; AZD 6244; CASPASE 3; CASPASE 7; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION FUNCTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION; WEIGHT REDUCTION;

ANIMALS; BENZIMIDAZOLES; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 7; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIVER NEOPLASMS; MAP KINASE KINASE KINASE 1; MICE; MICE, SCID; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33846781365     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0436     Document Type: Article

References (46)

1. Akriviadis EA, Llovet JM, Efremidis SC, et al. Hepatocellular carcinoma. Br J Surg 1998;85:1319-31.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
3. Schafer DF, Sorrell ME Hepatocellular carcinoma. Lancet 1999;353: 1253-7.
4. Inca N, Wands JR. The increasing incidence of hepatocellular carcinoma. N Engl J Med 1999;340:798-9.
5. Chedid A, Ryan LM, Dayal Y, Wolf BC, Falkson G. Morphology and other prognostic factors of hepatocellular carcinoma. Arch Pathol Lab Med 1999;123:524-8.
6. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
7. Colombo M. Hepatocellular carcinoma. J Hepatol 1992; 15:225-36.
8. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 1995;221: 291-8.
9. Takenaka K, Kawahara N, Yamamoto K, et al. Results of 280 liver resections for hepatocellular carcinoma. Arch Surg 1996; 131:71-6.
10. Huguet CSFaGA. Over-expression of the mitogen-activated protein kinase (MAP kinase). In: L Blumgart, editor. Surgery of the liver and biliary tract. London: Churchill Livingstone; 2000. p. 1365-69.
11. Lai EaWJ. Hepatocellular carcinoma: the Asian experience. In: L Blumgart, editor. Surgery of the liver and the biliary tract. London: Churchill Livingstone; 1994. p. 1349-63.
12. Chan ES, Chow PK, Tai B, Machin D, Soo K. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev 2000;2:CDO011991199.
13. Zeng JZ, Wang HY, Chen ZJ, Ullrich A, Wu MC. Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma. Oncogene 2002;21:4932-43.
14. Huynh H, Chow PK, Ooi LL, Soo KC. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 2002; 13: 115-22.
15. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47.
16. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18:813-22.
17. Amundadottir LT, Leder P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 1998;16:737-46.
18. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 1995;92:7686-9.
19. Nguyen DH, Catling AD, Webb DJ, et al. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol 1999;146:149-64.
20. Liu E, Thant AA, Kikkawa F, et al. The Ras-mitogen-activated protein kinase pathway is critical for the activation of matrix metalloproteinase secretion and the invasiveness in v-crk-transformed 3Y1. Cancer Res 2000;60:2361-4.
21. Reddy KB, Krueger JS, Kondapaka SB, Diglio CA. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int J Cancer 1999;82:268-73.
22. Anderson NG, Mailer JL, Tonks NK, Sturgill TW. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 1990;343:651-3.
23. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 2001; 12:397-408.
24. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270: 27489-94.
25. Frodin M, Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 1999;151: 65-77.
26. Huynh HT, Nguyen TT, Chow PK, Tan PH, Soo KC, Tran E. Over-expression of MEK-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 2003;3:19.
27. Huynh H, Do PT, Nguyen TH, etal. Extracellularsignal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma. Int J Oncol 2004;25:1839-47.
28. Lee P, Wallace E, Yeh T, et al. Demonstration of broad in vivo anti-tumour activity of ARRY-142886 (AZD6244), a potent and selective MEK inhibitor [abstract]. Array BioPharma 2005.
29. Winkler JD, Lee PA, Wallace E, et al. Anti-tumor activity, pharmaco-kinetic and pharmacodynamic effects of the MEK inhibitor ARRY-142886 (AZD6244) in a BxPC3 pancreatic tumor xenograft model [abstract]. Array BioPharma 2005.
30. Huynh H, Soo KC, Chow PK, Panasci L, Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 2006;12:4306-14.
31. Hung H. Suppression of ps20 expression in the rat uterus by tamoxifen and estrogens. Endocrinology 2005; 146:2388-96.
32. Nguyen TT, Tran E, Ong CK, et al. Kaempferol-induced growth inhibition and apoptosis in A549 lung cancer cells is mediated by activation of MEK-MAPK. J Cell Physiol 2003;197:110-21.
33. Alessi DR, Cohen P, Ashworth A, Cowley S, Leevers SJ, Marshall CJ. Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Methods Enzymol 1995;255:279-90.
34. Mikula M, Schreiber M, Husak Z, et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J 2001;20: 1952-62.
35. Dalby KN, Morrice N, Caudwell FB, Avruch J, Cohen P. Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK) -activated protein kinase-la/p90rsk that are inducible by MAPK. J Biol Chem 1998;273:1496-505.
36. Chang M, Sexl V, Sherr CJ, Roussel MF. Assembly of cyclin D- dependent kinase and titration of p27Kip1 regulated by mitogen- activated protein kinase kinase (MEK1). Proc Natl Acad Sci U S A 1998; 95:1091-6.
37. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996;271:20608-16.
38. Brondello JM, McKenzie FR, Sun H, Tonks NK, Pouyssegur J. Constitutive MAP kinase phosphatase (MKP-1) expression blocks G1 specific gene transcription and S-phase entry in fibroblasts. Oncogene 1995;10:1895-904.
39. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down- regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151:1523-30.
40. 3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998; 140:1255-63.
41. Simon C, Juarez J, Nicolson GL, Boyd D. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion. Cancer Res 1996;56:5369-74.
42. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. An induced proximity model for caspase-8 activation. J Biol Chem 1998;273: 2926-30.
43. Cryns V, Yuan J. Proteases to die for. Genes Dev 1998;12: 1551-70.
44. Cai J, Yang J, Jones DP. Mitochondrial control of apoptosis: the role of cytochrome c. Biochim Biophys Acta 1998; 1366:139-49.
45. Zou H, Li Y, Liu X, Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999;274:11549-56.
46. Sharma P, Veeranna, Sharma M, et al. Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway. J Biol Chem 2002;277:528-34.